The greater infectivity of Leishmania parasites leads to treatment failure

According to a new study published in the journal of the American Society for Microbiology it says that the Leishmania parasites can lead to treatment failure due to greater infectivity. The drug was thought of a resistant but it turned quite opposite. This could increase the danger.

 This research was in connection due with the visceral leishmaniasis, popularly known as kala-azar. This is basically a parasitic disease that hit more 400,000 people every year this big killer kills 10 percent of its victim. The study aimed to find whether the miltefosine treatment can deal with the increased infectivity of the parasite or not. Also to find can it be a decreasing or controlling ingredient or not. This research have cleared many misconceptions.

 The co-researcher, Manu Vanaerschot of the Institute of Tropical Medicine in Antwerp, Belgium explains the study, “Parasites from relapsed patients show an increased capacity to infect host cells.”